Academic Journal
View in EDS
HTML Full Text

COVID-19 Vaccination Recommendations for Immunocompromised Patient Populations: Delphi Panel and Consensus Statement Generation in the United States.

Bibliographic Details
Title: COVID-19 Vaccination Recommendations for Immunocompromised Patient Populations: Delphi Panel and Consensus Statement Generation in the United States.
Authors: Lai, Kira Zhi Hua1 (AUTHOR), Greenstein, Stuart2 (AUTHOR), Govindasamy, Rajesh3 (AUTHOR), Paranilam, Jaya1 (AUTHOR), Brown, Joseph1 (AUTHOR), Kimball-Carroll, Samantha1 (AUTHOR) Samantha.kimball@iconplc.com
Source: Infectious Diseases & Therapy. Nov2024, Vol. 13 Issue 11, p2255-2283. 29p.
Subject Terms: *SARS-CoV-2, *BOOSTER vaccines, *COVID-19, *MESSENGER RNA, *PHYSICIANS
Abstract: Introduction: The United States Advisory Committee on Immunization Practices (ACIP) and the Centers for Disease Control (CDC) recommend COVID-19 vaccines for all immunocompromised individuals. Certain disease groups are at increased risk of comorbidity and death for which disease-specific recommendations should be considered. The objective of the Delphi panel of experts was to summarize expert consensus on COVID-19 vaccinations for patients with rheumatologic disease, renal disease, hematologic malignancy and solid organ transplant (SOT) in the US. Methods: A two-stage Delphi panel method was employed, starting with qualitative interviews with key opinion leaders (KOLs) in the four disease areas (n = 4 KOLs, n = 16 total) followed by three rounds of iterative revision of disease-specific COVID-19 vaccine recommendations. Final consensus was rated after the third round. Statements addressed primary and booster dosing (e.g., number and frequency) and other considerations such as vaccine type or heterologous messenger ribonucleic acid (mRNA) vaccination. Following the Delphi Panel, an online survey was conducted to assess physician agreement within the disease areas (n = 50 each, n = 200 total) with the consensus statements. Results: Moderate to strong consensus was achieved for all primary series vaccination statements across disease groups, except one in hematology. Similarly, moderate to strong consensus was achieved for all booster series statements in all disease areas. However, statements on antibody titer measurements for re-vaccination considerations and higher dosages for immunocompromised patients did not reach agreement. Overall, approximately 62%–96% of physicians strongly agreed with the primary and booster vaccine recommendations. However, low agreement (29%–69%) was found among physicians for time interval between disease-specific treatment and vaccination, recommendations for mRNA vaccines, heterologous mRNA vaccination, antibody titer measurement and higher vaccine dosage for immunocompromised groups. Conclusion: Consensus was achieved for disease-specific COVID-19 vaccine recommendations concerning primary and booster series vaccines and was generally well accepted by practicing physicians. [ABSTRACT FROM AUTHOR]
Copyright of Infectious Diseases & Therapy is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Academic Search Complete
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
CustomLinks:
  – Url: https://resolver.ebsco.com/c/xy5jbn/result?sid=EBSCO:a9h&genre=article&issn=21938229&ISBN=&volume=13&issue=11&date=20241101&spage=2255&pages=2255-2283&title=Infectious Diseases & Therapy&atitle=COVID-19%20Vaccination%20Recommendations%20for%20Immunocompromised%20Patient%20Populations%3A%20Delphi%20Panel%20and%20Consensus%20Statement%20Generation%20in%20the%20United%20States.&aulast=Lai%2C%20Kira%20Zhi%20Hua&id=DOI:10.1007/s40121-024-01052-8
    Name: Full Text Finder (for New FTF UI) (s8985755)
    Category: fullText
    Text: Find It @ SCU Libraries
    MouseOverText: Find It @ SCU Libraries
Header DbId: a9h
DbLabel: Academic Search Complete
An: 180457831
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: COVID-19 Vaccination Recommendations for Immunocompromised Patient Populations: Delphi Panel and Consensus Statement Generation in the United States.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Lai%2C+Kira+Zhi+Hua%22">Lai, Kira Zhi Hua</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Greenstein%2C+Stuart%22">Greenstein, Stuart</searchLink><relatesTo>2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Govindasamy%2C+Rajesh%22">Govindasamy, Rajesh</searchLink><relatesTo>3</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Paranilam%2C+Jaya%22">Paranilam, Jaya</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Brown%2C+Joseph%22">Brown, Joseph</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Kimball-Carroll%2C+Samantha%22">Kimball-Carroll, Samantha</searchLink><relatesTo>1</relatesTo> (AUTHOR)<i> Samantha.kimball@iconplc.com</i>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Infectious+Diseases+%26+Therapy%22">Infectious Diseases & Therapy</searchLink>. Nov2024, Vol. 13 Issue 11, p2255-2283. 29p.
– Name: Subject
  Label: Subject Terms
  Group: Su
  Data: *<searchLink fieldCode="DE" term="%22SARS-CoV-2%22">SARS-CoV-2</searchLink><br />*<searchLink fieldCode="DE" term="%22BOOSTER+vaccines%22">BOOSTER vaccines</searchLink><br />*<searchLink fieldCode="DE" term="%22COVID-19%22">COVID-19</searchLink><br />*<searchLink fieldCode="DE" term="%22MESSENGER+RNA%22">MESSENGER RNA</searchLink><br />*<searchLink fieldCode="DE" term="%22PHYSICIANS%22">PHYSICIANS</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: Introduction: The United States Advisory Committee on Immunization Practices (ACIP) and the Centers for Disease Control (CDC) recommend COVID-19 vaccines for all immunocompromised individuals. Certain disease groups are at increased risk of comorbidity and death for which disease-specific recommendations should be considered. The objective of the Delphi panel of experts was to summarize expert consensus on COVID-19 vaccinations for patients with rheumatologic disease, renal disease, hematologic malignancy and solid organ transplant (SOT) in the US. Methods: A two-stage Delphi panel method was employed, starting with qualitative interviews with key opinion leaders (KOLs) in the four disease areas (n = 4 KOLs, n = 16 total) followed by three rounds of iterative revision of disease-specific COVID-19 vaccine recommendations. Final consensus was rated after the third round. Statements addressed primary and booster dosing (e.g., number and frequency) and other considerations such as vaccine type or heterologous messenger ribonucleic acid (mRNA) vaccination. Following the Delphi Panel, an online survey was conducted to assess physician agreement within the disease areas (n = 50 each, n = 200 total) with the consensus statements. Results: Moderate to strong consensus was achieved for all primary series vaccination statements across disease groups, except one in hematology. Similarly, moderate to strong consensus was achieved for all booster series statements in all disease areas. However, statements on antibody titer measurements for re-vaccination considerations and higher dosages for immunocompromised patients did not reach agreement. Overall, approximately 62%–96% of physicians strongly agreed with the primary and booster vaccine recommendations. However, low agreement (29%–69%) was found among physicians for time interval between disease-specific treatment and vaccination, recommendations for mRNA vaccines, heterologous mRNA vaccination, antibody titer measurement and higher vaccine dosage for immunocompromised groups. Conclusion: Consensus was achieved for disease-specific COVID-19 vaccine recommendations concerning primary and booster series vaccines and was generally well accepted by practicing physicians. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of Infectious Diseases & Therapy is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://login.libproxy.scu.edu/login?url=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=a9h&AN=180457831
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s40121-024-01052-8
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 29
        StartPage: 2255
    Subjects:
      – SubjectFull: SARS-CoV-2
        Type: general
      – SubjectFull: BOOSTER vaccines
        Type: general
      – SubjectFull: COVID-19
        Type: general
      – SubjectFull: MESSENGER RNA
        Type: general
      – SubjectFull: PHYSICIANS
        Type: general
    Titles:
      – TitleFull: COVID-19 Vaccination Recommendations for Immunocompromised Patient Populations: Delphi Panel and Consensus Statement Generation in the United States.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Lai, Kira Zhi Hua
      – PersonEntity:
          Name:
            NameFull: Greenstein, Stuart
      – PersonEntity:
          Name:
            NameFull: Govindasamy, Rajesh
      – PersonEntity:
          Name:
            NameFull: Paranilam, Jaya
      – PersonEntity:
          Name:
            NameFull: Brown, Joseph
      – PersonEntity:
          Name:
            NameFull: Kimball-Carroll, Samantha
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 11
              Text: Nov2024
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-print
              Value: 21938229
          Numbering:
            – Type: volume
              Value: 13
            – Type: issue
              Value: 11
          Titles:
            – TitleFull: Infectious Diseases & Therapy
              Type: main
ResultId 1